RBC Capital lowered the firm’s price target on Teleflex (TFX) to $150 from $155 and keeps an Outperform rating on the shares as part of a broader research note previewing Q1 results for Medical Devices. Q1 underlying procedure volume and capital placements trends were solid with typical seasonality at play, which should position companies under coverage to beat expectations for the quarter, while FX has moved notably to favor large-cap medical device companies with international exposure, which is not factored into consensus estimates for Q1 or 2025, the analyst tells investors in a research note. Tariff impact is likely to be clarified by several companies, though many companies under coverage have low tariff exposure with a substantial U.S. manufacturing footprint or low relative exposure vs. other large caps, the firm adds.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TFX:
- Teleflex price target lowered to $140 from $149 at Truist
- Teleflex’s Strategic Uncertainty and Growth Challenges Justify Hold Rating
- Teleflex receives FDA 510(k) clearance of AC3 Range IABP
- Teleflex reports efficacy of Ringer PBC in coronary procedures
- Teleflex updates clinical study data on UroLift System in BPH